Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study

Table 1 Demographic and clinical characteristics of patients, n (%)

Variable	All patients		P value	Matched patients		P value
	NAC and surgery (n = 36)	Surgery first (n = 108)		NAC and surgery (n = 36)	Surgery first (n = 36)
Age, yr (mean ± SD)	52 ± 11	57 ± 12	< 0.05	51.6 ± 11.4	49.9 ± 12.2	0.531
Sex			0.307			1
Male	21 (58.3)	75 (69.4)		21 (58.3)	21 (58.3)
Female	15 (41.7)	33 (30.6)		15 (41.7)	15 (41.7)
BMI, kg/m2 (mean ± SD)	24.1 ± 50	23.7 ± 3.4	0.527	24.1 ± 5.0	23.6 ± 3.4	0.649
ASA			0.731			1
I-II	34 (94.4)	99 (91.7)		34 (94.4)	33 (91.7)
III-IV	2 (5.6)	9 (8.3)		2 (5.6)	3 (8.3)
Comorbidity			0.152			1
Absent	28 (77.8)	68 (63.0)		28 (77.8)	27 (75.0)
Present	8 (22.2)	40 (37.0)		8 (22.2)	9 (25.0)
Tumor location			0.069			0.896
Upper	4 (11.1)	32 (29.6)		4 (11.1)	5 (13.9)
Middle	13 (36.1)	36 (33.3)		13 (36.1)	14 (38.9)
Lower	19 (52.8)	40 (37.0)		19 (52.8)	17 (47.2)
Clinical T stage			1			0.462
3	15 (41.7)	46 (42.6)		15 (41.7)	11 (30.6)
4	21 (58.3)	62 (57.4)		21 (58.3)	25 (69.4)
Clinical N stage			< 0.05			0.514
0	4 (11.1)	35 (32.4)		4 (11.1)	7 (19.4)
1-3	32 (88.9)	73 (67.6)		32 (88.9)	29 (80.6)
Clinical TNM stage			0.181			0.829
IIB	4 (11.1)	27 (25.0)		4 (11.1)	6 (16.7)
III	29 (80.6)	70 (64.8)		29 (80.6)	28 (77.8)
IVA	3 (8.3)	11 (10.2)		3 (8.3)	2 (5.6)

NAC: Neoadjuvant chemotherapy; BMI: Body mass index; ASA: American Society of Anesthesiologists.